What was the primary driver of Gilead's revenue growth in Q1 2003?

The primary driver of Gilead's revenue growth was the significant increase in sales of Viread®, its HIV treatment medication. Viread sales more than tripled year-over-year, contributing $107.3 million in the first quarter of 2003.

What led to Gilead's large net loss in Q1 2003?

The significant net loss of $438.1 million was primarily due to a substantial charge of $488.6 million for in-process research and development (IPR&D) related to the acquisition of Triangle Pharmaceuticals. This acquisition expanded Gilead's pipeline but resulted in a large non-cash charge.

How did the acquisition of Triangle Pharmaceuticals impact Gilead's financial position?

The acquisition of Triangle Pharmaceuticals for $525.2 million significantly expanded Gilead's drug pipeline, particularly for HIV and Hepatitis B. Financially, it led to a large IPR&D charge, a decrease in cash and marketable securities due to the purchase price, and increased R&D expenses related to Triangle's acquired development programs.

What is the outlook for AmBisome sales in 2003?

Gilead expects full-year AmBisome sales to be in the range of $160 million to $170 million for 2003, representing a decrease of approximately 10% to 15% compared to 2002, due to increased competition in European markets.

GILD 10-Q Quarterly Report Q1 FY2003 — Revenue, Net Income, EPS

Summary

Gilead Sciences, Inc. reported significant revenue growth in its first quarter of 2003, driven primarily by a substantial increase in Viread sales. Total revenues more than doubled year-over-year, reflecting the growing adoption of Viread for HIV treatment. However, this top-line growth was overshadowed by a substantial net loss, largely attributable to a significant in-process research and development (IPR&D) charge related to the acquisition of Triangle Pharmaceuticals. The acquisition of Triangle Pharmaceuticals for $525.2 million expanded Gilead's pipeline in antiviral therapies, notably with emtricitabine for HIV and hepatitis B. While this strategic move bolsters future potential, the immediate financial impact included an $488.6 million IPR&D charge, leading to a reported net loss of $438.1 million. Despite the net loss, the company's operating cash flow showed improvement compared to the prior year, and its liquidity position remains adequate, with substantial cash and marketable securities, although reduced by the acquisition.

Key Highlights

1Total revenues surged to $165.1 million in Q1 2003, up from $78.4 million in Q1 2002, a 111% increase.
2Viread product sales more than tripled, reaching $107.3 million in Q1 2003, becoming the primary revenue driver.
3The acquisition of Triangle Pharmaceuticals for $525.2 million significantly expanded Gilead's antiviral pipeline, particularly for HIV and Hepatitis B.
4A substantial charge of $488.6 million for in-process research and development (IPR&D) related to the Triangle acquisition resulted in a net loss of $438.1 million for Q1 2003.
5Despite the net loss, cash provided by operating activities improved to $20.9 million in Q1 2003, compared to a use of $23.1 million in Q1 2002.
6Cash and cash equivalents, including marketable securities, stood at $612.1 million at the end of Q1 2003, a decrease from $942.4 million at year-end 2002, primarily due to the Triangle acquisition.
7Research and development expenses increased by 23% to $41.1 million, largely due to clinical trials for emtricitabine acquired from Triangle.

GILEAD SCIENCES, INC. Quarterly Report for Q1 Ended Mar 31, 2003

Summary

Key Highlights

Frequently Asked Questions